Kızılay, OsmanAkarsu Acar, Özge Pınar2023-04-202023-04-2020220882-05381744-5205https://doi.org/10.1080/08820538.2022.2100713https://hdl.handle.net/20.500.11776/10827Purpose To evaluate the best-corrected visual acuity (BCVA), the spherical equivalent (SE), and the central, parafoveal, and perifoveal macular thickness results of the children with a history of treated or spontaneously regressed retinopathy of prematurity (ROP). Methods Seventy-nine right eyes of 79 children at the age of 5 years old were included in this cross-sectional observational study. Twenty-four infants who received intravitreal bevacizumab (IVB) were in group 1, 27 infants who underwent laser photocoagulation (LPC) were in group 2, and 28 infants who had spontaneous regression were in group 3. Central foveal thickness (CFT) and the thicknesses of four parafoveal and four perifoveal quadrants as superior, temporal, inferior, and nasal were analyzed by using swept-source optical coherence tomography (SS-OCT). Results BCVA was significantly better (p = .002), and the SE was significantly higher in group 3 than in both groups 1 and 2 (p = .033). CFT was significantly lower in group 3 than in both groups 1 and 2 (p < .001). The parafoveal average, temporal, inferior, and nasal thickness values and the perifoveal average, superior, and temporal thickness results were significantly higher in group 2 than in both groups 1 and 3 (p = .003, p = .002, p = .009, and p = .009, respectively) (p = .003, p < .001, and p = .007, respectively). Conclusion CFT was significantly higher in infants who had treatment for ROP. Parafoveal and perifoveal retinal thicknesses in certain quadrants were higher in those receiving LPC treatment than in others. CFT was negatively correlated with both gestational age and birth weight. Myopia was seen more often in children who had treatment.en10.1080/08820538.2022.2100713info:eu-repo/semantics/openAccessIntravitreal BevacizumabLaser PhotocoagulationRetinopathy Of PrematuritySpontaneous RegressionSwept-Source Optical Coherence TomographyChoroidal ThicknessSpectral-DomainBevacizumabPretermInfantsArticle376780785Q4WOS:0008254421000012-s2.0-8513416739335834678Q2